Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Danaher Corp (NY:DHR)

201.02 -4.80 (-2.33%)
Streaming Delayed Price Updated: 12:57 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Danaher Corp

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
It's Time for Some Enthusiasm for Small-Cap Stocks
After a year and a half of big names pushing the market forward, some smaller companies are starting to go on a run. 
Via The Motley Fool
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Freeport-McMoRan is Bryn Talkington's "final trade." On July 23, Freeport-McMoRan said second-quarter revenue came in at $6.62 billion. 
Via Benzinga
Demystifying Danaher: Insights From 5 Analyst Reviews
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Market Whales and Their Recent Bets on DHR Options
 
Via Benzinga
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
(DHR) - Analyzing Danaher's Short Interest
 
Via Benzinga
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Here's Why Danaher Stock Surged Today
The biotechnology, diagnostics, and life sciences company looks set to return to its long-term growth rate. 
Via The Motley Fool
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Key Takeaways From Danaher Analyst Ratings
 
Via Benzinga
DHR Stock Earnings: Danaher Beats EPS, Beats Revenue for Q2 2024
DHR stock results show that Danaher beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Medical Giant Danaher Nears Breakout On This 'Stark Contrast' With A Key Rival
The company kept its outlook for the year, which differs from Sartorius' cut last week. 
Via Investor's Business Daily
Life Science Giant Danaher's Q2 Earnings Beat Estimates On 'Sustained Positive Momentum In Bioprocessing Business', Maintains Guidance
Danaher reported a 3% year-over-year decline in Q2 sales to $5.743 billion, surpassing the $5.59 billion consensus. Adjusted EPS was $1.72, beating expectations of $1.57. CEO Rainer Blair highlighted... 
Via Benzinga
Topics Earnings
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Find out which five stocks saw an increase in reader interest during the trading week and how the stocks reacted. 
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today
 
Via Benzinga
Danaher Unusual Options Activity For June 13
 
Via Benzinga
Peering Into Danaher's Recent Short Interest
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 CEOs Who Could Steer Boeing Back to Clear Skies
Boeing is on the hunt for a new CEO to fix all that ails it. Some of the highest-paid CEOs will be considered for the turnaround. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years
 
Via Benzinga
What the Options Market Tells Us About Danaher
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
How Is The Market Feeling About Danaher?
 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Beijing’s Sino Biological completed its $48 million acquisition of Vancouver-based SignalChem Biotech. Additionally, Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.